Compare GPRE & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GPRE | GERN |
|---|---|---|
| Founded | 2004 | 1990 |
| Country | United States | United States |
| Employees | N/A | 258 |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 812.2M | 808.3M |
| IPO Year | 2004 | N/A |
| Metric | GPRE | GERN |
|---|---|---|
| Price | $17.06 | $1.43 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $12.57 | $2.17 |
| AVG Volume (30 Days) | 1.3M | ★ 10.3M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.42 | N/A |
| Revenue | ★ $2,091,680,000.00 | N/A |
| Revenue This Year | N/A | $26.91 |
| Revenue Next Year | $11.85 | $43.75 |
| P/E Ratio | $40.95 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.08 | $1.04 |
| 52 Week High | $19.65 | $2.01 |
| Indicator | GPRE | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.76 | 53.59 |
| Support Level | $14.01 | $1.39 |
| Resistance Level | $17.94 | $1.46 |
| Average True Range (ATR) | 0.96 | 0.08 |
| MACD | 0.04 | -0.01 |
| Stochastic Oscillator | 40.46 | 27.78 |
Green Plains Inc manufactures and sells ethanol and ethanol byproducts in two segments based on function. The ethanol production segment, which generates the majority of revenue, includes the production of ethanol, distillers grains, Ultra-High Protein and renewable corn oil. The agribusiness and energy services segment includes grain handling and storage, commodity marketing and merchant trading for company-produced and third-party ethanol, distillers grains, Ultra-High Protein, renewable corn oil, natural gas and other commodities.
Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.